MannKind Corporation reported Q2 2026 total revenues of $109,374 (thousands), a 43% increase from Q2 2025, driven by the addition of Furoscix, higher collaborations and services revenue, and royalties tied to Tyvaso DPI. Commercial product sales were $41,982 (thousands), including Furoscix net sales of $22,191 (thousands) and Afrezza net sales of $17,021 (thousands). For the first six months of 2026, total revenues reached $199,544 (thousands), up 29% year over year.
Higher cost of goods, research and development, and selling, general and administrative expenses, largely associated with Furoscix and pipeline advancement, led to a Q2 2026 net loss of $19,032 (thousands), or $0.06 per basic share, compared with net income of $668 (thousands) a year earlier. Non-GAAP adjusted net loss was $2,660 (thousands) versus non-GAAP income of $13,901 (thousands). Cash, cash equivalents and investments totaled $111 million as of June 30, 2026, and a $50 million private placement closed on July 24, 2026 to fund a $45 million contingent value right payment following FDA approval of the Furoscix ReadyFlow autoinjector. During 2026, MannKind also received FDA approval for a pediatric indication for Afrezza and reported positive Phase 1b data for its nintedanib DPI program while preparing an IND for ralinepag DPI.
Vanguard Capital Management LLC and certain affiliates report passive ownership of MannKind Corp common stock on Schedule 13G. They beneficially own 15,450,421 shares, representing 5% of the outstanding common stock as of June 30, 2026.
Vanguard has sole voting power over 2,281,029 shares and sole dispositive power over all 15,450,421 shares, with no shared voting or dispositive power. The position is held across Vanguard funds and managed accounts, and no other single underlying investor is reported to hold more than 5% of the class through these holdings.
MannKind Corporation completed a $50.0 million private placement with institutional accredited investors, selling 10,440,838 shares of common stock at $3.89 per share and pre-funded warrants for 2,412,632 underlying shares at $3.88 per warrant share. The pre-funded warrants have a $0.01 exercise price, are exercisable on a cashless basis, do not expire until fully exercised, and include a beneficial ownership limitation not to exceed 19.99%.
The company plans to use net proceeds for general corporate purposes, including funding a $45.0 million contingent value rights payment obligation triggered by the U.S. Food and Drug Administration’s approval of Furoscix ReadyFlow (furosemide injection). The securities were issued under the Section 4(a)(2) exemption, with resale registration rights for the shares and warrant shares to be filed within 30 days of closing. Separately, the FDA approved Furoscix ReadyFlow to treat edema in adults with heart failure or chronic kidney disease.
MANNKIND CORP Chief Financial Officer Christopher B. Prentiss reported two tax-withholding dispositions of common stock on July 15, 2026, totaling 22,247 shares at $4.09 per share. The shares were delivered or withheld to satisfy exercise price or tax liabilities upon vesting of previously reported restricted stock units under Rule 16b-3. His reported direct holdings include 1,991 shares acquired through the Employee Stock Purchase Plan on June 30, 2026.
MannKind Corp reports that Dominic Marasco, President of the Endocrine Business Unit, had 3,623 shares of common stock withheld on July 15, 2026 at $4.09 per share as a tax-withholding disposition related to the vesting of previously reported restricted stock units under Rule 16b-3. Following this transaction, he directly holds 343,398 shares, including 2,775 shares acquired through the Employee Stock Purchase Plan on June 30, 2026.
MannKind Corp Chief People & Workpl Officer Stuart A. Tross had a previously granted performance restricted stock unit award vest on July 15, 2026, delivering 93,790 shares of common stock. To cover taxes, a total of 65,808 shares were withheld at $4.09 per share, and his direct holdings include shares acquired through the Employee Stock Purchase Plan.
MannKind Corp reports that CEO Michael Castagna had a performance-based restricted stock unit award granted on May 25, 2023 vest on July 15, 2026, delivering 350,260 common shares after achieving 83% of target performance. The original 422,000-unit grant left 71,740 units forfeited. On the same date, an aggregate 363,200 shares of common stock were withheld or delivered at $4.09 per share to satisfy exercise price or tax obligations related to equity awards.
MannKind Corp EVP Technical Operations Sanjay R. Singh reported vesting of a performance-based restricted stock unit award granted in May 2023, delivering 70,550 common shares on July 15, 2026. Footnotes state performance goals were achieved at 83% of target, with 14,450 units forfeited. To satisfy tax obligations, 46,795 shares were withheld at $4.09 per share and characterized as payments of tax liability by delivering or withholding shares under Rule 16b-3. Each restricted stock unit represented one share of common stock.
David Thomson, EVP, General Counsel & Secretary of MannKind, acquired 93,790 shares of common stock on July 15, 2026 through vesting of a performance RSU award, while 19,210 shares were forfeited under the plan. To cover taxes, 98,426 shares were withheld at about $4.09 per share. On July 17, he sold 24,109 shares at a weighted average of $4.05 under a Rule 10b5-1 plan established December 2, 2025, leaving 797,554 shares held directly.
MannKind Corp director Steven B. Binder reported multiple equity transactions. On July 15, 2026, a performance RSU award granted in 2023 vested at 83% of target, delivering 93,790 shares and forfeiting 19,210. Shares totaling 24,395 were withheld to cover taxes. On July 17, 2026, he sold 52,485 shares of common stock at a weighted average price of $4.06, in open-market transactions under a Rule 10b5-1 plan established December 2, 2025. After these transactions, he directly holds 824,918 shares of MannKind common stock.